AmnioBed™ Technology Is The Future
The AmnioBed™ has the potential to significantly reduce short and long-term costs associated with premature births, including short-term benefits for doctors and caregivers as well as long-term benefits to the infants who avoid serious lifelong complications. The AmnioBed™ has the potential to reduce the length of stay (LOS) for these infants, thus saving significant direct costs of the NICU visit in addition to the infants' improved comfort.
- The neonatal intensive care unit (NICU) costs per day can run as much as $8,500.
- A four-day stay in the NICU by a very premature infant typically costs between $40,000 and $80,000.
- Improve clinical outcomes for the estimated 110,000 PTB infants born in the US each year.
- A conservative goal of a 3-day reduction in NICU will result in over $1.1 Billion in savings associated with PTB infants (under 34 weeks of gestational age).
Why you should invest with Amnion Life
Be advised that AmnioBed is not for sale at this time - information on the website is strictly for investment purposes only.
"Caution - Investigational Device, Limited by Federal (or United States) Law to Investigational Use."
Amnion Life LLC - is led by the founder, Amir Fassihi, M.D., who is an accomplished Radiologist currently practicing in Orange County, California. The engineering team has proven to be highly capable, and experienced consultants have been engaged to focus on areas such as legal & regulatory, business strategy, and finances.
US Patent No. 15,342,988 and US Patent No 10,166,161 - Intellectual Property (IP) is represented by Knobbe and Martens law firm who specializes in Intellectual Property strategy, both defensive patent aggregation (DPA) and offensive patent aggregation (OPA).
The AmnioBed™ and other technology produced by Amnion Life LLC - will be focused primarily on nurturing newborns, especially preterm birth (PTB) infants. We are also in the process of assembling a medical advisory board to further this goal.
Introducing AmnioBed™ - Our Flagship Product
Incubators are critical to the PTB population and especially Amnion Life’s target PTB segments of Very Premature and Extremely Premature infants. Current incubator technology does NOT adequately address the known complications associated with early development.
There are approximately 388,000 preterm births (PTBs) in the US each year and of those PTB’s, ¹-³ an estimated 110,000 could benefit from the many advantages of the AmnioBed. These infants represent the most severe PTBs including the very preterm, extremely preterm and very low birth weight (VLBW).
The target PTB infant population has a high risk of complications in the short and long-term plus the highest rate of infant death. And there are also significant costs associated with this PTB infant population beginning at birth, and for many, complications and associated costs that are lifelong.
Get Involved With Amnion Life
If you would like to learn more about our investment opportunities or would like investment documents such as an Executive Summary, please provide your name and email below. We will contact you as soon as we are available.